Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX – Research Report), Walgreens Boots Alliance (WBA – Research Report) and Kodiak Sciences (KOD – Research Report).
OptimizeRx (OPRX)
Barclays analyst Stephanie Davis maintained a Hold rating on OptimizeRx today and set a price target of $15.00. The company’s shares closed last Thursday at $12.15.
According to TipRanks.com, Davis has 0 stars on 0-5 stars ranking scale with an average return of
OptimizeRx has an analyst consensus of Moderate Buy, with a price target consensus of $16.33.
See today’s best-performing stocks on TipRanks >>
Walgreens Boots Alliance (WBA)
Barclays analyst Steven Valiquette maintained a Sell rating on Walgreens Boots Alliance today and set a price target of $21.00. The company’s shares closed last Thursday at $21.69, close to its 52-week low of $19.68.
According to TipRanks.com, Valiquette is ranked #6188 out of 8778 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Walgreens Boots Alliance with a $24.00 average price target, a 16.5% upside from current levels. In a report issued on March 28, Bank of America Securities also maintained a Sell rating on the stock with a $22.00 price target.
Kodiak Sciences (KOD)
In a report released today, Gena Wang from Barclays maintained a Sell rating on Kodiak Sciences, with a price target of $3.00. The company’s shares closed last Thursday at $5.26.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Kodiak Sciences with a $3.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OPRX:
- OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
- OptimizeRx cuts FY24 revenue view to at least $100M from at least $110M
- OptimizeRx backs FY23 revenue view at least $68M-$70M, consensus $69.85M
- OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
- OptimizeRx Powers Walmart’s ‘Specialty Pharmacies of the Community’ Outreach Effort
